Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Net sales increased due to the recovery in sales of toric and multifocal lenses, which had been affected by delivery delays, expanded sales of the SEED AirGrade series, and growth in sales through cross-border e-commerce in China. Personnel expenses associated with increased staffing and improved employee compensation, as well as research and development expenses related to clinical trials, increased and put downward pressure on operating profit.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥8,848 million (YoY +3.5%) |
| Operating profit | ¥618 million (YoY -2.0%) |
| Ordinary income | ¥517 million (YoY -14.9%) |
| Profit attributable to owners of the parent | ¥336 million (YoY -11.9%) |
| Net income per share | ¥11.10 |
| Equity ratio | End of the current fiscal period 28.9 / End of previous period 30.8 |
| Total assets | ¥66,133 million |
| Net assets | ¥19,081 million |
| Cash flows from operating activities | ¥861 million |
| Cash flows from investing activities | ¥-7,009 million |
| Cash flows from financing activities | ¥7,674 million |
| Cash and cash equivalents at end of period | ¥5,750 million |
| Full-year earnings forecast | Net Sales ¥37,000 million (YoY +9.0%) / Operating profit ¥2,200 million (YoY +52.8%) / Ordinary income ¥1,750 million (YoY +24.5%) / Profit attributable to owners of the parent ¥1,350 million (YoY +18.9%) |
| Annual Dividend Forecast | ¥15 → ¥15（0.0%） |
| Segment revenue | Contact Lenses and Lens Care Products ¥8,832 million (YoY +3.6%), Other ¥16 million (YoY -20.1%) |
| Segment profit | Contact Lenses and Lens Care Products ¥1,019 million (YoY -7.3%), Other ¥1 million (YoY -9.9%) |
| Depreciation and amortization | ¥1,069 million |
| Impairment loss | None (the segment information states that there were no applicable items for the period) |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥2,251 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 1 / Name of newly added company 株式会社オキュデバイセズ / Excluded 0 / Excluded Company Name Not disclosed |
| Material subsequent events | Effective 1 July 2026, the smart contact lens business was transferred to 株式会社オキュデバイセズ through a company split. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 30,265,922 |
| Treasury Shares at Period-End | 136 |
| Factors Behind Changes in Business Performance | Net sales increased due to the recovery in sales of toric and multifocal lenses, which had been affected by delivery delays, expanded sales of the SEED AirGrade series, and growth in sales through cross-border e-commerce in China. Personnel expenses associated with increased staffing and improved employee compensation, as well as research and development expenses related to clinical trials, increased and put downward pressure on operating profit. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Net sales increased due to the recovery in sales of toric and multifocal lenses, expanded sales of the SEED AirGrade series, and growth in sales through cross-border e-commerce in China. Selling, general and administrative expenses increased, however, mainly because of higher personnel expenses associated with increased staffing and improved employee compensation, as well as higher research and development expenses related to clinical trials, putting downward pressure on profit.